Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
INCB-057643
Contact us for more batch information
INCB-057643
Catalog No. T5417Cas No. 1820889-23-3
INCB057643 is a potent, selective and orally bioavailable BET inhibitor.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $68 | In Stock | |
| 2 mg | $98 | In Stock | |
| 5 mg | $169 | In Stock | |
| 10 mg | $289 | In Stock | |
| 25 mg | $548 | In Stock | |
| 50 mg | $779 | In Stock | |
| 100 mg | $1,060 | In Stock | |
| 500 mg | $2,130 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $183 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "INCB-057643"
(6R)-FR054
T893410378-06-0
(6R)-FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect.
- $39
Size
QTY
Ginkgolide B
Cited
T275115291-77-7
Ginkgolide B (BN-52021) is a PAFR antagonist(IC50=3.6 μM) isolated from Ginkgo biloba.
- $57
Size
QTY
CitedBS-181 Cited
T19471092443-52-1
BS-181 is a highly selective CDK7 inhibitor (IC50: 21 nM); >40-fold selective for CDK7 than CDK1/2/4/5/6/9.
- $88
Size
QTY
Cited2-Thiocytidine
TNU043613239-97-9
2-Thiocytidine is a purine nucleoside analog that targets malignant tumors of the inert lymphatic system and has a broad spectrum of antitumor activity.2-Thiocytidine induces apoptosis by inhibiting DNA synthesis.2-Thiocytidine is a purine nucleoside analog that targets malignant tumors of the inert lymphatic system.
- $32
Size
QTY
Apitolisib
T19161032754-93-0
Apitolisib (RG 7422), an effective, class I PI3K inhibitor for PI3Kα(IC50=5 nM), PI3Kβ(IC50=27 nM), PI3Kδ(IC50=7 nM), PI3Kγ (IC50=14 nM), is used in trials study of solid cancers, breast cancer, prostate cancer, renal cell carcinoma, and endometrial carcinoma, among others.
- $38
Size
QTY
Devimistat
T615795809-78-2
Devimistat (6,8-Bis(benzylthio)octanoic acid) , a lipoate analog, inhibits mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, disrupts tumor cell mitochondrial metabolism. It has potential chemopreventive and antineoplastic activities, and has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.
- $53
Size
QTY
GNE-900
T712591200126-26-6
GNE-900 is an ATP-competitive ChK1 inhibitor with selective and oral activity.GNE-900 inhibits ChKl and ChK2 with IC50 values of 0.0011 and 1.5 µM, respectively.GNE-900 enhances DNA damage and induces apoptosis. GNE-900 has antitumor activity.
- $67
Size
QTY
Paederosidic acid
T573918842-98-3
Paederosidic acid has significant anti-tumor, anticonvulsant and sedative effects. Paederosidic acid increases brain gamma-aminobutyric acid and decreases glutamic acid in the brain, and it up-regulates expressions of GAD 65, may be a promising future the
- $130
Size
QTY
EGFR-IN-12
T5168879127-07-8
EGFR-IN-12 (EGFR Inhibitor) is a cell permeable and selective inhibitor of EGFR kinase (IC50: 21 nM) and blocks receptor autophosphorylation in cells.
- $75
Size
QTY
CMLD-2
T36493958843-91-9
CMLD-2 is an inhibitor of HuR-ARE interaction (Ki: 350 nM) that competitively binds HuR protein and disrupts its interaction with adenine element-rich (ARE) mRNA targets.CMLD-2 induces apoptosis and exhibits antitumor effects through MAD2 downregulation. CMLD-2 (1-75 μM ; 24-72 h) had an inhibitory effect on the viability of thyroid cancer cells.CMLD-2 (20-30 μM ; 24-48 h) activated caspases and induced apoptosis in H1299 and A549 cells.CMLD-2 (30 μM ; 24-48 h) induced G1 cell cycle arrest in H1299 and A549 cells and mitochondrial perturbation. CMLD-2 (30 μM ; 24-48 h) reduced the expression of HuR and HuR-regulated mRNAs and proteins in H1299 cells.CMLD-2 (35 μM ; 72 h) decreased the directional migration ability of SW1736, 8505C, BCPAP and K1 cells.CMLD-2 induced the migration of SW1736, 8505C, BCPAP and K1 cells with a strong decrease in MAD2 mRNA levels.
- $98
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | INCB057643 is a potent, selective and orally bioavailable BET inhibitor. |
| In vitro | INCB057643 inhibited binding of BRD2/BRD3/BRD4 to an acetylated histone H4 peptide in the low nM range and was selective against other bromodomain-containing proteins. INCB057643 inhibited proliferation of human AML, DLBCL, and multiple myeloma cell lines, with a corresponding decrease in MYC protein levels. Cell cycle analyses indicated that G1 arrest and a concentration-dependent increase in apoptosis were seen within 48 hours of treatment with INCB057643. BRD proteins also regulate the expression of many pro-inflammatory genes. Production of several cytokines, including IL-6, IL-10 and MIP-1α, was repressed by INCB057643 in human and mouse whole blood stimulated ex vivo with LPS [1]. |
| In vivo | Oral administration of INCB057643 resulted in significant anti-tumor efficacy in xenograft models of AML, myeloma, and DLBCL. Additionally, combining INCB057643 with the standard of care agents used for the treatment of DLBCL including rituximab and bendamustine resulted in enhanced anti-tumor efficacy relative to that achieved with single-agent therapies at doses that were well tolerated [1]. |
| Molecular Weight | 415.46 |
| Formula | C20H21N3O5S |
| Cas No. | 1820889-23-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 65 mg/mL (156.45 mM)  | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.